Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock Has Average Price Target of $47.50

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $47.50.

A number of equities analysts have weighed in on ASMB shares. UBS Group assumed coverage on Assembly Biosciences in a research report on Tuesday, September 1st. They issued a “buy” rating and a $52.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, Mizuho set a $53.00 price objective on shares of Assembly Biosciences in a research report on Tuesday, September 1st.

Assembly Biosciences Trading Down 2.5%

Assembly Biosciences stock opened at $22.18 on Friday. Assembly Biosciences has a 12 month low of $21.80 and a 12 month high of $39.71. The stock has a fifty day simple moving average of $28.96 and a two-hundred day simple moving average of $27.83. The firm has a market cap of $451.61 million, a price-to-earnings ratio of 21.75 and a beta of 1.15.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The firm had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. On average, equities research analysts forecast that Assembly Biosciences will post 2.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

A number of hedge funds have recently added to or reduced their stakes in ASMB. Seven Fleet Capital Management LP purchased a new position in shares of Assembly Biosciences in the 4th quarter worth $147,000. Bank of America Corp DE grew its holdings in shares of Assembly Biosciences by 113.3% in the first quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 5,792 shares during the period. Renaissance Technologies LLC increased its position in Assembly Biosciences by 69.4% during the first quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 6,411 shares during the last quarter. Engineers Gate Manager LP increased its position in Assembly Biosciences by 88.5% during the second quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company’s stock valued at $488,000 after acquiring an additional 8,343 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Assembly Biosciences in the second quarter valued at about $660,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral diseases. The company’s research programs target viral replication and other essential processes, with an emphasis on treatments that may improve outcomes for patients with limited therapeutic options.

Assembly’s pipeline has included investigational therapies for chronic hepatitis B virus (HBV) infection, including core or capsid assembly modulators designed to interfere with the virus’s life cycle.